Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349) recently posted soft earnings but shareholders didn’t react strongly. We did some analysis and found some concerning details beneath the statutory profit number.
See our latest analysis for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
The Impact Of Unusual Items On Profit
For anyone who wants to understand Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd’s profit beyond the statutory numbers, it’s important to note that during the last twelve months statutory profit gained from CN¥40m worth of unusual items. We can’t deny that higher profits generally leave us optimistic, but we’d prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that’s exactly what the…
